Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis System

Launched by SHANDONG UNIVERSITY · Jul 3, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a new artificial intelligence (AI) system to help doctors evaluate a condition known as Gastric Intestinal Metaplasia (GIM), which can be a risk factor for gastric cancer. The goal is to make it easier and faster for pathologists to assess the severity of GIM by analyzing images of biopsies taken during a gastroscopy, a procedure where a thin tube is used to look inside the stomach. Currently, the standard method requires multiple biopsies, which can be difficult due to a shortage of pathologists and a large number of people needing screening.

To be eligible for this trial, participants need to be between 40 and 75 years old and scheduled for a gastroscopy and biopsy. However, those with severe health issues or previous stomach surgeries, or who cannot consent, will not be included. If you join the study, you can expect to undergo the standard biopsy procedure, and your samples will be analyzed using this new AI system, which aims to provide quicker and more accurate results. This research could help improve how we assess and manage gastric cancer risk in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients aged 40-75 years who undergo the gastroscopy examination and biopsy
• Exclusion Criteria:
• • patients with severe cardiac, cerebral, pulmonary or renal dysfunction or psychiatric disorders who cannot participate in gastroscopy
• • patients with previous surgical procedures on the stomach
• • patients with contraindications to biopsy
• • patients who refuse to sign the informed consent form